Early Infliximab in Crohn’s is associated with decreased intestinal surgery and similar health care costs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early Infliximab in Crohn’s is associated with decreased intestinal surgery and similar health care costs

Published:2021-02-17 Issue:4 Volume:56 Page:397-402
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Singh H.¹²,Nguyen T.¹,Pho C.³,Giles E.¹²⁴

Affiliation:

1. Department of Paediatrics, Monash University, Melbourne, Australia

2. Department of Gastroenterology, Monash Children’s Hospital, Melbourne, Australia

3. Department of Pharmacy, Monash Children’s Hospital, Melbourne, Australia

4. Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, Australia

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2021.1880626

Reference23 articles.

1. Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication

2. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

3. Current global trends in the incidence of pediatric-onset inflammatory bowel disease

4. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

5. Natural history of Crohnʼs disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease;Alimentary Pharmacology & Therapeutics;2024-04-21

2. Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis;Inflammatory Bowel Diseases;2023-07-28

3. Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments;Journal of Crohn's and Colitis;2023-03-19

4. Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease;Alimentary Pharmacology & Therapeutics;2022-11-09

5. Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study;Frontiers in Pediatrics;2022-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3